Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment
Authors:
- 4 October 2009
- journal article
- review article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 50 (11) , 1773-1784
Abstract
Natural killer/T-cell (NK/T) lymphomas represent a group of rare tumors of NK and NK-T cells. The World Health Organization classifies NK-cell tumors into three types, extranodal NK/T-cell lymphomas (ENKL, nasal and non-nasal), NK-cell leukemias, and a blastic variant (CD4-positive, CD56-positive hematodermic neoplasms). We focus our review to the current concepts in biology and treatment of ENKL. Though considerable advances have been made in our understanding of NK-cell biology, malignant transformation including the role of Epstein–Barr virus, and prognosis, the rare nature of ENKL and its heterogeneity limit the ability to standardize therapy. Radiotherapy is fundamental to treatment of early-stage disease with a role for chemoradiotherapy among high-risk patients. The clinical course of advanced disease is highly aggressive with frequent chemotherapy resistance and a poor prognosis. Therapeutic approaches to advanced-stage or relapsed and refractory disease, including the appropriate sequence of chemotherapy, combined modality therapy, and stem cell transplantation is not well-established. International and multicenter clinical trials are needed for this rare and aggressive disease.Keywords
This publication has 86 references indexed in Scilit:
- Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: Japan Clinical Oncology Group Study JCOG0211Journal of Clinical Oncology, 2009
- Natural killer cell neoplasmsCancer, 2008
- Phase I study of dexamethasone, methotrexate, ifosfamide, l ‐asparaginase, and etoposide (SMILE) chemotherapy for advanced‐stage, relapsed or refractory extranodal natural killer (NK)/T‐cell lymphoma and leukemiaCancer Science, 2008
- Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transferBlood, 2007
- Progress in understanding and managing natural killer‐cell malignanciesBritish Journal of Haematology, 2007
- Effect of Positive Bone Marrow EBV In situ Hybridization in Staging and Survival of Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal-TypeClinical Cancer Research, 2007
- NK/T-cell lymphomas ‘nasal type’: an Italian multicentric retrospective surveyAnnals of Oncology, 2006
- First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy ± radiotherapy is active in stage I/II extranodal NK/T-cell lymphomaLeukemia & Lymphoma, 2006
- Extranodal nasal type NK/T-cell Lymphoma: Elucidating clinical prognostic factors for risk-based stratification of therapyEuropean Journal of Cancer, 2005
- Nasal Lymphomas in Japan: A High Prevalence of Epstein-Barr VirusTypeA and Deletion Within the Latent Membrane Protein GeneLeukemia & Lymphoma, 1999